[Form 4] ARTIVION, INC. Insider Trading Activity

Rhea-AI Filing Summary

Artivion, Inc. (AORT) senior vice president and general counsel Jean F. Holloway reported option exercises and related stock sales in November 2025. On November 14, 2025, she exercised options to acquire 6,393 shares of common stock at $29.62 per share and sold 6,393 shares at $45.00 per share, leaving 169,801 shares owned directly, then 163,408 shares after the sale. On November 17, 2025, she exercised options for 6,394 shares at $29.62 and sold 6,394 shares at $45.17, with 169,802 shares shown after the exercise and 163,408 shares directly owned after the sale.

The derivative table shows these transactions came from stock options granted with a $29.62 exercise price and an expiration date of March 5, 2026. The filing notes that the option exercises and subsequent sales were carried out under a Rule 10b5-1 trading plan adopted on August 14, 2025, and that the options vested in equal annual installments beginning March 5, 2020.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holloway Jean F

(Last) (First) (Middle)

1655 ROBERTS BLVD., NW

(Street)

KENNESAW GA 30144

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		M		6,393(1)	A	$29.62	169,801	D
Common Stock	11/14/2025		S		6,393(1)	D	$45	163,408	D
Common Stock	11/17/2025		M		6,394(1)	A	$29.62	169,802	D
Common Stock	11/17/2025		S		6,394(1)	D	$45.17	163,408	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$29.62	11/14/2025		M			6,393(1)	03/05/2020(2)	03/05/2026	Common Stock	6,393	$0	0	D
Stock Options (Right to buy)	$29.62	11/17/2025		M			6,394(1)	03/05/2020(2)	03/05/2026	Common Stock	6,394	$0	0	D

Explanation of Responses:

1. The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025.

2. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020.

Remarks:

	/s/ Jean F Holloway	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Artivion (AORT) report on this Form 4?

The Form 4 reports that Jean F. Holloway, Artivion’s senior vice president and general counsel, exercised stock options and sold common shares of Artivion, Inc. (AORT) in two sets of transactions on November 14, 2025 and November 17, 2025.

How many Artivion (AORT) shares did the insider exercise and sell?

On November 14, 2025, she exercised options for 6,393 shares and sold 6,393 shares. On November 17, 2025, she exercised options for 6,394 shares and sold 6,394 shares of Artivion common stock.

At what prices were the Artivion (AORT) option exercises and sales made?

The stock options had an exercise price of $29.62 per share. The resulting share sales were reported at $45.00 per share on November 14, 2025 and $45.17 per share on November 17, 2025.

How many Artivion (AORT) shares does the reporting person own after these transactions?

After each reported sale, the Form 4 shows that 163,408 shares of Artivion common stock were beneficially owned directly by the reporting person.

Were the Artivion (AORT) insider transactions made under a Rule 10b5-1 plan?

Yes. The explanation states that the option exercises and subsequent sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2025.

What are the key terms of the Artivion (AORT) stock options exercised?

The stock options carried an exercise price of $29.62 per share, an expiration date of March 5, 2026, and vested at a rate of 33 1/3% per year beginning on the first anniversary of the grant date, with the first exercisable date on March 5, 2020.